Anupam Rama
Stock Analyst at JP Morgan
(4.44)
# 299
Out of 5,241 analysts
276
Total ratings
51.02%
Success rate
20.96%
Average return
Main Sectors:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Overweight | $177 → $185 | $158.42 | +16.78% | 23 | May 8, 2026 | |
| TRAX First Tracks Biotherapeutics | Initiates: Overweight | $31 | $16.90 | +83.43% | 1 | Apr 23, 2026 | |
| REPL Replimune Group | Downgrades: Underweight | n/a | $5.22 | - | 13 | Apr 13, 2026 | |
| MAZE Maze Therapeutics | Maintains: Overweight | $52 → $58 | $25.56 | +126.92% | 3 | Mar 31, 2026 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $44 → $41 | $42.59 | -3.73% | 5 | Mar 25, 2026 | |
| SLDB Solid Biosciences | Maintains: Overweight | $11 → $12 | $6.92 | +73.41% | 10 | Mar 25, 2026 | |
| ZLAB Zai Lab | Maintains: Overweight | $39 → $32 | $20.59 | +55.42% | 14 | Mar 18, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $55 → $58 | $13.59 | +326.78% | 7 | Mar 18, 2026 | |
| ERAS Erasca | Maintains: Overweight | $24 → $25 | $10.23 | +144.38% | 2 | Mar 18, 2026 | |
| CTMX CytomX Therapeutics | Upgrades: Overweight | $7 → $12 | $3.61 | +232.41% | 4 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $74 | $25.00 | +196.00% | 4 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $89 → $94 | $66.13 | +42.14% | 13 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $45 | $20.23 | +122.44% | 12 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $32 | $10.55 | +203.32% | 1 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $99 → $96 | $37.32 | +157.23% | 12 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $67 | $32.68 | +105.02% | 9 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $40 | $14.63 | +173.41% | 2 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $147 → $145 | $102.30 | +41.74% | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $7 → $6 | $9.06 | -33.77% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $20 | $8.15 | +145.40% | 7 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $13.41 | +26.77% | 1 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 → $24 | $37.02 | -35.17% | 8 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $79 | $28.21 | +180.04% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.31 | - | 1 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $24 | $17.55 | +36.75% | 17 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $80 | $63.15 | +26.68% | 12 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $56.51 | -29.22% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.66 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.30 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $5.21 | +149.52% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $9.58 | +2,509.60% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.22 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $75.85 | -23.53% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $16.22 | -26.02% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $8.79 | +320.93% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $102.18 | -46.17% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $14 → $38 | $10.28 | +269.65% | 13 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $28.17 | +91.69% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $2,250 | $4.27 | +52,593.21% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $17.29 | +56.16% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $286.98 | -52.26% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $8.97 | +435.12% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $2.47 | +1,114.57% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $71.47 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.58 | - | 2 | Jul 21, 2017 |
Neurocrine Biosciences
May 8, 2026
Maintains: Overweight
Price Target: $177 → $185
Current: $158.42
Upside: +16.78%
First Tracks Biotherapeutics
Apr 23, 2026
Initiates: Overweight
Price Target: $31
Current: $16.90
Upside: +83.43%
Replimune Group
Apr 13, 2026
Downgrades: Underweight
Price Target: n/a
Current: $5.22
Upside: -
Maze Therapeutics
Mar 31, 2026
Maintains: Overweight
Price Target: $52 → $58
Current: $25.56
Upside: +126.92%
Travere Therapeutics
Mar 25, 2026
Maintains: Overweight
Price Target: $44 → $41
Current: $42.59
Upside: -3.73%
Solid Biosciences
Mar 25, 2026
Maintains: Overweight
Price Target: $11 → $12
Current: $6.92
Upside: +73.41%
Zai Lab
Mar 18, 2026
Maintains: Overweight
Price Target: $39 → $32
Current: $20.59
Upside: +55.42%
Olema Pharmaceuticals
Mar 18, 2026
Maintains: Overweight
Price Target: $55 → $58
Current: $13.59
Upside: +326.78%
Erasca
Mar 18, 2026
Maintains: Overweight
Price Target: $24 → $25
Current: $10.23
Upside: +144.38%
CytomX Therapeutics
Mar 16, 2026
Upgrades: Overweight
Price Target: $7 → $12
Current: $3.61
Upside: +232.41%
Mar 12, 2026
Maintains: Overweight
Price Target: $120 → $74
Current: $25.00
Upside: +196.00%
Mar 10, 2026
Maintains: Overweight
Price Target: $89 → $94
Current: $66.13
Upside: +42.14%
Mar 9, 2026
Maintains: Overweight
Price Target: $33 → $45
Current: $20.23
Upside: +122.44%
Mar 3, 2026
Initiates: Overweight
Price Target: $32
Current: $10.55
Upside: +203.32%
Dec 19, 2025
Maintains: Overweight
Price Target: $99 → $96
Current: $37.32
Upside: +157.23%
Dec 19, 2025
Maintains: Overweight
Price Target: $65 → $67
Current: $32.68
Upside: +105.02%
Dec 19, 2025
Maintains: Overweight
Price Target: $43 → $40
Current: $14.63
Upside: +173.41%
Dec 19, 2025
Maintains: Overweight
Price Target: $147 → $145
Current: $102.30
Upside: +41.74%
Nov 18, 2025
Maintains: Underweight
Price Target: $7 → $6
Current: $9.06
Upside: -33.77%
Nov 18, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $8.15
Upside: +145.40%
Nov 14, 2025
Initiates: Overweight
Price Target: $17
Current: $13.41
Upside: +26.77%
Oct 24, 2025
Upgrades: Overweight
Price Target: $15 → $24
Current: $37.02
Upside: -35.17%
Oct 23, 2025
Maintains: Overweight
Price Target: $74 → $79
Current: $28.21
Upside: +180.04%
Sep 16, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.31
Upside: -
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $17.55
Upside: +36.75%
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $63.15
Upside: +26.68%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $56.51
Upside: -29.22%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $1.66
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $14.30
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $5.21
Upside: +149.52%
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $9.58
Upside: +2,509.60%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.22
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $75.85
Upside: -23.53%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $16.22
Upside: -26.02%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $8.79
Upside: +320.93%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $102.18
Upside: -46.17%
Oct 11, 2021
Upgrades: Neutral
Price Target: $14 → $38
Current: $10.28
Upside: +269.65%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $28.17
Upside: +91.69%
Jan 11, 2021
Initiates: Overweight
Price Target: $2,250
Current: $4.27
Upside: +52,593.21%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $17.29
Upside: +56.16%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $286.98
Upside: -52.26%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $8.97
Upside: +435.12%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $2.47
Upside: +1,114.57%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $71.47
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.58
Upside: -